MIRA INFORM REPORT

Report Date :

07.09.2011

IDENTIFICATION DETAILS

Name :	EPOCH PHARMACEUTICALS

Registered Office :	Plot No. 83 - 85, Sector-15, Korangi Industrial Area, Karachi

Country :	Pakistan

Year of Establishment :	1995

Legal Form :	Partnership Concern

Line of Business :	Manufacture & Marketing of Pharmaceutical Products

RATING & COMMENTS

MIRA’s Rating :

RATING		STATUS	PROPOSED CREDIT LINE
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small

Status :	Moderate

Payment Behaviour :	No Complaints

Litigation :	Clear

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List – March 31^st, 2011

Country Name

Previous Rating

(31.12.2010)

Current Rating

(31.03.2011)

Pakistan

Risk Category	ECGC Classification
Insignificant	A1
Low	A2
Moderate	B1
High	B2
Very High	C1
Restricted	C2
Off-credit	D

Bottom of Form

Business Name

EPOCH PHARMACEUTICALS

Full Address

Registered Address & Factory

Plot No. 83 - 85, Sector-15, Korangi Industrial Area, Karachi, Pakistan

Tel #	92 (21) 35050480, 35050481
Fax #	92 (21) 35061940

Short Description Of Business

a.	Nature of Business	Engaged in Manufacture & Marketing of Pharmaceutical Products
b.	Year Established	1995

Legal Status

Subject Concern was established as a Partnership business in 1995

Details of Managing Partner / Partners

Names

Address

Occupation

Designation

Mr. Muhammad Saleem Aboobaker

Mrs. Aboobaker Osman

Plot No. 83 - 85, Sector-15, Korangi Industrial Area, Karachi

Business

Managing Partner

Partner

Associates

A. Subsidiary

None

B. Associated Companies

- Do -

Product/Services

Engaged in manufacture & marketing of Pharmaceutical Products by its brand names of ACRIVINE, AKTIS, ASTHAMOL, BCOPLEX, BICOLAX, CEPAXIN, CURAZINE, DEXADRON, DINCLOR, DIPYROL, DOXCIL, ECOXIB, EFOMYCIN, EPOCEF, EPOCILLIN, EPOCLOR, EPOCLOX, EPOFIX, EPOFLOX, EPOMET, EPOPHENICOL, EPOSPAN, EPOSTAN, EPOTAZIME, EPOVEL, EPOXCIL, EPOXYLIN, EPOZOL, EPRIN, EPROFEN, EPTHROCIN, EROGENT, FENACLOD, FLUGINAL, FRAGAN, GENTA, GENTACORT, INSTAGEN, LERAQUIN, LESFIBRO, LOPHASE, LYSOTOP, MAGNACID, MECZE, METCLOMIDE, NEOSAL, PHENERZINE, PRIXIME, PROCOTIL, PROSPERIN, RHEUCAM, SEPTROZOLE, SIDIC, SIDICORT, SKENAZOLE, SODOCEF, TANAMOL, THONIUM, XETIN

Number of Employees

145

Capacity & Production

The capacity and production of the concern’s plant is indeterminable as it is multi- product and involves various processes of manufacture.

Annual Sales Volume

(In Pak Rupees)

Year	In Pak Rupees
2009	200,000,000/- (Estimated)

Trade Suppliers

(Foreign)

(1) LAKE CHEMICAL LTD., INDIA.
(2) KUNSHAN CHEMICAL CO LTD, CHINA.
(3) CHANGZHOU SUNCHEM CHEMICAL CO LTD, CHINA.

Distribution Network

Mainly exist at major cities of Pakistan

Bankers

(1) Faysal Bank Limited, Pakistan.

(2) Bank Al-Habib Limited, Pakistan.

(3) Standard Chartered Bank, Pakistan.

(4) MCB Bank Limited, Pakistan.

(5) Habib Bank Limited, Pakistan.

Memberships

· Karachi Chamber of Commerce & Industry.(KCCI)

· Pakistan Pharmaceutical Manufacturers Association.(PPMA)

Foreign Exchange Rates

Currency	Unit	Pakistani Rupee
US Dollar	1	Rs. 87.05
UK Pound	1	Rs. 140.30
Euro	1	Rs. 121.80

Comments

Subject Concern was established in 1995 and is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation is satisfactory. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	Rs.46.13
UK Pound	1	Rs.74.18
Euro	1	Rs.64.88

RATING EXPLANATIONS

RATING		STATUS	PROPOSED CREDIT LINE
>86	Aaa	Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums	Unlimited
71-85	Aa	Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums	Large
56-70	A	Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums	Fairly Large
41-55	Ba	Overall operation is considered normal. Capable to meet normal commitments.	Satisfactory
26-40	B	Capability to overcome financial difficulties seems comparatively below average.	Small
11-25	Ca	Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity	Limited with full security
<10	C	Absolute credit risk exists. Caution needed to be exercised	Credit not recommended
----	NB	New Business	----

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

Financial condition (40%) Ownership background (20%) Payment record (10%)

Credit history (10%) Market trend (10%) Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.